About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, March 31st, 2017

The QualityStocks
Daily Stock List


Innovative Food Holdings, Inc. (IVFH)

The Bowser Report, Marketbeat, Stock Guru, and FeedBlitz reported earlier on Innovative Food Holdings, Inc. (IVFH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Innovative Food Holdings, Inc. is an industry leading specialty food platform. The Company, through its subsidiaries, is a top nationwide provider of direct from source specialty foods, healthcare foods, gluten free foods, and artisanal foods, to the professional foodservice market. Perishable product is delivered direct to the Company’s kitchen the next day via overnight delivery. Non-perishable product is delivered direct to customers.

Innovative Food Holdings is based in Bonita Springs, Florida. The Company’s wholly-owned subsidiary is Artisan Specialty Foods. Innovative Food Holdings lists on the OTC Markets Group’s OTCQB.

Innovative Food Holdings serves restaurants, hotels, country clubs, national chain accounts, casinos, and catering houses. Many of its products are used each day by a multitude of some of the leading professional chefs across the U.S. Innovative Food Holdings supplies chefs with innovative, organic, sustainable, and artisanal products sourced from all regions around the world. The Company markets its products directly to the consumer, by way of its website at www.forthegourmet.com/.

In the direct-to-chef foodservice market, the Company’s automated direct-to-chef platform provides efficient, cost effective, and transparent direct sourcing and distribution of more than 7,000 specialty food products delivered daily, to thousands of chefs across the country.    

Available products include origin specific seafood, exotic meats and game, dry-aged meats, exotic fruits and vegetables, specialty chocolates, artisanal cheeses, and imported specialties. Available products also include caviar, wild and cultivated mushrooms, micro-greens, heirloom and baby produce, organic farmed and manufactured food products, estate-bottled olive oils, aged vinegars, and healthcare food products.

The Company’s Artisan Specialty Foods is a nationwide specialty food distributer, re-packer, and importer. Artisan serves hundreds of customers in the Chicago area. In addition, it serves as a nationwide fulfillment center for other Innovative Food Holdings subsidiaries operating in the foodservice and direct-to-consumer markets.

Yesterday, Innovative Food Holdings announced results for Q4 and the full year ended December 31, 2016. For Q4 2016, Revenue grew 16 percent to $9.7 million versus $8.4 million for Q4 of 2015 Net Income was $993,000 versus a loss of $59,000 for Q4 of 2015.

For the Full Year ended December 31, 2016, Revenue grew 15 percent to $35 million versus $30.6 million for the full year 2015. Net Income was $2.8 million versus a loss of $373,000 for the full year 2015.

Innovative Food Holdings, Inc. (IVFH), closed Friday's trading session at $0.65, up 38.30%, on 566,279 volume with 213 trades. The average volume for the last 60 days is 44,357 and the stock's 52-week low/high is $0.34/$0.57.

Rightscorp, Inc. (RIHT)

Stock Commander, PennyStocks24, PennyPickAlerts, Fortune Stock Alerts, TheNextBigTrade, BestDamnPennyStocks, DSR News, Penny Stock Hub, StocksImpossible, Broad Street, OTCBB Journal, PHUB News, MarketWireStocks, PennyDoctor, Pennystocktweeters.com, Wallstreet Profiler, and Stock News Now reported earlier on Rightscorp, Inc. (RIHT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Rightscorp, Inc. is the leading provider of monetization services for artists and holders of copyrighted Intellectual Property (IP). The Company’s patent pending digital loss prevention technology focuses on the infringement of digital content, including music, movies, software, and games. This technology ensures that owners and creators are rightfully paid for IP. In essence, Rightscorp is a foremost provider of data and analytic services to support artists and owners of copyrighted property. Rightscorp is headquartered in Santa Monica, California.

The Company works closely with its clients to develop programs of education and notice, and as necessary to pursue copyright infringers for their illegal file sharing activities through notifications sent via Internet Service Providers (ISPs). Rightscorp implements existing laws to solve copyright infringements through collecting payments from illegal file sharing activities through the sent notifications.

Rightscorp's commitment is to the vision that digital creative works should be protected economically so that the next generation of music, movies, video games, and software can be made and its creators can prosper. The Company’s technology identifies copyright infringers, who are offered a reasonable settlement option versus the legal liability defined in the Digital Millennium Copyrights Act (DMCA). Rightscorp has monetized major media titles through relationships with industry leaders.

Rightscorp uses software that monitors the global Peer‐to‐ Peer (P2P) file sharing networks to seek out and find illegally downloaded digital media. Infringers remit payment to Rightscorp for the copyright infringement and the Company makes payment to the copyright owners.

In October of 2015, Rightscorp announced that the Australian Commissioner of Patents granted Australian Patent 2012236069, for Rightscorp's "System to Identify Multiple Copyright Infringements". This patent will expire on April 2, 2032. This marks Rightscorp's first patent in Australia.

Last month, Rightscorp announced the transition of its Executive Management Team that will include the appointment of Mr. Cecil Bond Kyte as the Company's new Chief Executive Officer (CEO). Mr. Christopher Sabec, the Company's present CEO, will serve as President and continue to lead Rightscorp's Intellectual Property (IP) litigation support and copyright monetization services with the content industry's top artists, creators, and copyright holders.

Rightscorp, Inc. (RIHT), closed Friday's trading session at $0.0205, up 13.89%, on 426,200 volume with 13 trades. The average volume for the last 60 days is 123,907 and the stock's 52-week low/high is $0.0102/$0.085.

PositiveID Corp. (PSID)

SmallCapVoice, Value Penny Stocks, RedChip, MassiveStockProfits, Penny Stock Titans, PennyDoctor, Wallstreet Profiler, Beacon Equity Research, Equity Observer, GrowthPennyStocks, HotStockProfits, InvestorSoup, Jet-Life Penny Stocks, Penny Stock General, Penny Stocks Finder, Shiznit Stocks, Stock Preacher, SuperStockTips, and Value Penny Stocks reported on PositiveID Corp. (PSID), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

A life sciences company, PositiveID Corp. is a developer of biological detection and diagnostics solutions. The Company is a developer of biological detection systems for the U.S. Homeland Defense industry and rapid biological testing. Its focus is on the development of microfluidic systems for the automated preparation of and performance of biological assays to detect biological threats at high-value locations and analyze samples in a medical environment. PositiveID acquired MicroFluidic Systems (MFS) in May of 2011.

PositiveID is based in Delray Beach, Florida. The Company’s shares trade on the OTCQB. PositiveID is also a leader in the mobile technology vehicle market, with an emphasis on the laboratory market and homeland security.

MicroFluidic Systems (MFS) specializes in the development and production of automated instruments for detecting and processing biological samples. Its core technology is used for airborne pathogen detection, rapid clinical diagnostics, and sample preparation applications.

Concerning Molecular Diagnostics, PositiveID’s products include M-BAND and Firefly. The Microfluidics-based Bioagent Networked Detector (M-BAND) developed by MicroFluidic Systems (MFS) is a bioaerosol monitor with fully integrated systems with sample collection, processing, as well as detection modules.

PositiveID is developing the Firefly Dx detection system. Firefly Dx is its real-time, hand held, polymerase chain reaction (PCR) pathogen detection system. This system is a two-part device. It consists of a portable handheld instrument with wireless Bluetooth communication and disposable single-use cartridges containing all vital analytical elements.

PositiveID is developing Firefly Dx based on intellectual property (IP) and knowledge gained during years of development and $30 million of contract funding from the U.S. Department of Homeland Security for its M-BAND system. This system uses PCR for the identification of airborne bio-threats.

In October of 2015, PositiveID announced that it entered into an agreement to acquire the capital stock of Thermomedics, Inc. Thermomedics manufactures and markets the Food and Drug Administration (FDA)-cleared Caregiver® non-contact clinical-grade thermometer. This acquisition is a part of PositiveID’s total growth strategy to add revenue-generating, complementary products with considerable market penetration potential to its portfolio.

At the beginning of March, PositiveID announced that its Thermomedics subsidiary signed the Patient Safety Movement Foundation’s Open Data Pledge to share its data to promote patient safety among a list of greater than 70 healthcare technology companies. The Patient Safety Movement encourages healthcare technology companies to share the data for which their products are purchased.

In addition, this month, PositiveID announced that its E-N-G Mobile Systems subsidiary (ENG) is expanding its service offering to include mobile support and repairs on-call or under a service contract to help its customers lessen vehicle downtime. ENG is a specialty vehicle manufacturer. ENG designs and builds mobile laboratories, wireless support vehicles (cell-on-wheels and cell-on-light-trucks), radio frequency (RF) test platforms, broadcast news vehicles, and other technical vehicles.

PositiveID Corp. (PSID), closed Friday's trading session at $0.0002, up 33.33%, on 375,871,313 volume with 180 trades. The average volume for the last 60 days is 180,839,110 and the stock's 52-week low/high is $0.0001/$0.945.

OptimizeRx Corp. (OPRX)

Marketbeat, Streetwise Reports, and Bull in Advantage reported on OptimizeRx Corp. (OPRX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OptimizeRx Corp. provides innovative consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products. The Company does so while providing pharmaceutical and healthcare companies effective ways to expand awareness, access, and adherence to their medications. The Company’s core product is SampleMD. OptimizeRx is headquartered in Rochester, Michigan.
The Company’s SampleMD replaces drug samples with electronic trial vouchers and co-pay coupon savings. These are electronically added to an e-Prescription and sent electronically to the pharmacy and is integrated within leading Electronic Health Record (EHR) platforms in the nation. These include Allscripts, DrFirst, NewCrop, Quest Diagnostics, and Practice Fusion.

OptimizeRx initially launched its SampleMD e-coupon solution in April 2015 within Practice Fusion's EMR. The Company promotes patients’ savings and support from the world's largest pharmaceutical companies. These include Pfizer, Lilly, Novartis, AstraZeneca, and many others.

OptimizeRx has also launched its OPTIMZEHR™. This is its consulting and implementation practice to assist pharmaceutical-biotechnology companies and healthcare provider platforms in determining and executing on mutually beneficial opportunities to jointly assist physicians and patients within their electronic health record (EHR) workflow.

OptimizeRx has a new suite of services. These services integrate complete brand support into the EHR. This leads to enhanced patient care and improved outcomes. The new offerings include Brand Messaging and Brand Support.

The Company’s core product has been financial messaging, providing physicians with electronic coupons, co-pay offers, and vouchers for their patients at the point of care. OptimizeRx’s new brand support services include New Product Launch/ Drug File Integration; Sales Training and Support; and EHR Strategy and Planning.

Eye Care Leaders (ECL) has recently integrated with OptimizeRx.  Via a platform integration, ECL and OptimizeRx will provide cost saving and patient information services within EHRs that are part of ECL’s portfolio of performance solutions for over 6,800 ophthalmologists and optometrists. ECL is the leading provider of practice performance solutions for ophthalmologists and optometrists.

OptimizeRx has been considerably expanding its EHR channel partnerships. This has more than doubled the Company’s healthcare provider reach in the United States to over 500,000 since 2014.

OptimizeRx’s most recent partnership additions also include exclusive access to Allscripts EHR TouchWorks, with its advanced platform that supports some of the largest integrated delivery networks in the nation. OptimizeRx has grown to over 370 EHR and eRx network partnerships, which allow access at point of prescribe to greater than half of the HCPs in the United States.

OptimizeRx reported results this month for Q4 and full year ended December 31, 2016.  Net revenue was up 13 percent to a record $2.3 million in Q4 and up 7 percent to $7.8 million for the full year of 2016.

OptimizeRx Corp. (OPRX), closed Friday's trading session at $0.815, up 3.16%, on 60,055 volume with 18 trades. The average volume for the last 60 days is 21,710 and the stock's 52-week low/high is $0.65/$1.20.

NanoFlex Power Corp. (OPVS)

We are reporting on NanoFlex Power Corp. (OPVS) today, here at the QualityStocks Daily Newsletter.

NanoFlex Power Corp. engages in the research, development, and commercialization of advanced configuration solar technologies. These technologies enable inventive thin-film solar cell implementations. NanoFlex believes these will be industry-leading efficiencies, light weight, flexible, and low total system cost.  NanoFlex Power is based in Scottsdale, Arizona and the Company lists on the OTCQB.

The Company’s sponsored research programs at USC, Michigan, and Princeton University have resulted in a broad portfolio of issued and pending patents, worldwide, covering flexible, thin-film photovoltaic technologies. Its sponsored research programs with the University of Southern California and the University of Michigan have resulted in an IP portfolio consisting of greater than 700 issued or pending patents internationally.

Its research programs have produced two solar thin film technology platforms. These are: Gallium Arsenide (GaAs) thin film technology for high power applications and organic photovoltaic (OPV) technology for applications necessitating high quality aesthetics, such as semi-transparency and tinting and ultra-flexible form factors.

The targeting of these technologies is at specific wide-ranging applications. These include mobile and off-grid power generation; building applied photovoltaics (BAPV); and building integrated photovoltaics (BIPV). Moreover, these include space vehicles and unmanned aerial vehicles (UAVs); semi-transparent photovoltaic windows or glazing; and ultra-thin solar films or paints for automobiles or other consumer applications.

NanoFlex Power’s sponsored research agreements provide the Company with the exclusive global license and right to sublicense any and all intellectual property (IP) resulting from the related research and development (R&D) efforts at the above-mentioned universities.

NanoFlex Power is centering on two parallel technology development efforts. Its inorganic GaAs architectures, manufacturing processes, and technologies aim to provide solar cell manufacturers with the capability of producing thin film GaAs solar cells with ultra-high efficiencies at a cost less than $1 per watt for applications including mobile and field generation, BAPV, BIPV and aerospace that are not well-served by crystalline silicon solar technologies.

Also, the Company’s portfolio of OPV thin film solar technologies aim to provide low-cost and highly flexible solar energy solutions for new applications. These include BIPV (tinted or semi-transparent solar films for glass surfaces) and ultra-thin films for coatings on automobiles, and more.

Last month, NanoFlex Power announced it entered into a license agreement with SolAero Technologies Corporation. For the last two years, NanoFlex and SolAero have partnered to validate NanoFlex's patented, non-destructive epitaxial lift-off (ND-ELO) process and related technologies in SolAero's ultra-high efficiency solar cells. SolAero is a worldwide leader in high performance photovoltaics for space and terrestrial applications.

NanoFlex Power has the exclusive global rights to license, sublicense, and bring its own products to market utilizing ND-ELO technology. ND-ELO technology has the potential to decrease compound semiconductor production costs by over 40 percent through enabling reuse of the expensive wafer substrate. This pioneering process technology was invented at the University of Michigan by Professor Steven Forrest's research team. NanoFlex Power has further developed it.

NanoFlex Power Corp. (OPVS), closed Friday's trading session at $0.62, up 14.79%, on 2,325 volume with 3 trades. The average volume for the last 60 days is 15,652 and the stock's 52-week low/high is $0.201/$2.10.

Solitron Devices, Inc. (SODI)

Stock Profile reported previously on Solitron Devices, Inc. (SODI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Solitron Devices, Inc. designs, develops, manufactures and markets solid-state semiconductor components and related devices. These are largely for the military and aerospace markets. The Company concentrates on designing and manufacturing high performance, high density, high quality power components and circuitry.  OTCQB-listed, Solitron Devices is based in West Palm Beach, Florida.

The majority of the Company’s products are custom made pursuant to contracts with customers whose end products are sold to the United States government. Other products, including Joint Army/Navy transistors, diodes and Standard Military Drawings voltage regulators sell as standard or catalog items.

Since 1965, Solitron Devices has supplied components for greater than 200 Defense and Aerospace programs. The Company has a 47,000-sq. ft. manufacturing facility housing a 5K sq. ft. Class 10,000 clean room (FED-STD-209); and a 25K sq. ft. Class 100,000 clean room (FED-STD-209); and 39 laminar flow hoods provide Class 100 work areas.

Solitron customers include Lockheed Martin, Honeywell, BAE Systems, Raytheon, and General Dynamics. In addition, customers include Northrop Grumman, GE, Boeing, and L3 Communications.

Solitron Devices has a reputation for producing custom and standard power solid-state components for the aerospace, defense, industrial, medical, and commercial industries. Its advanced semiconductor device and packaging technology has contributed to the success of mostly every U.S. and European aerospace and defense program.

Solitron Devices provides support to all analog and mixed signal designs, whether they are power or small signal hybrids. The Company considers support of digital and high frequency modules on a case-by-case basis. It supports small, medium and large volume requirements and supports COTS (Commercial Off-The-Shelf) of all products it makes.

The Company is at the vanguard of semiconductor packaging and device thermal management. Over the years, the Company has designed and manufactured more than 400 different package styles. Solitron’s capabilities include Space Level Processing; Engineering, Manufacturing; Off-Shore Assembly; as well as In-House Testing.

Solitron is an innovator and leader in Thick-Film Power Hybrid Technology. It provides a wide variety of sophisticated power MOSFETs, BIPOLAR power transistors and SCHOTTKY rectifiers/diodes power hybrid circuits that incorporate Small Signal, Monolithic Integrated Circuits and Power Semiconductors into a single "mini" package.

Solitron Devices manufactures a wide array of bipolar and metal oxide semiconductor (MOS) power transistors, power and control hybrids, junction and power MOS field effect transistors (Power MOSFETS), field effect transistors, and other related products. The Company’s hybrids are either standard or custom made to meet customer requirements.

Solitron Devices, Inc. (SODI), closed Friday's trading session at $4.20, up 2.44%, on 1,500 volume with 2 trades. The average volume for the last 60 days is 4,425 and the stock's 52-week low/high is $3.35/$4.45.


The QualityStocks
Company Corner


ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.37, off by 2.63%, on 311,448 volume with 143 trades. The stock’s average daily volume over the past 60 days is 106,591 and its 52-week low/high is $0.05/$2.09.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring ORHub, Inc. (OTC: ORHB), an NNW client providing its cloud-based health care software-as-a-service (SaaS) to decrease costs and improve outcomes in surgical care. The publication is entitled, "Health Care Industry in Need of Unitary Data Processing Solution over Existing Legacy Systems." It provides an overview of issues with the health care industry's existing approach to data, and the need for an overarching intelligence technology system that can pull all available information together. To view the full article, visit: https://www.networknewswire.com/health-care-industry-need-unitary-data-processing-solution-existing-legacy-systems/

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

NetworkNewsWire Announces Publication on Solutions for the Health Care Industry's Data Processing Needs

NetworkNewsWire Announces Publication of Discussion on the Value of IT & Big Data Analytics for the Health Care Industry

NetworkNewsWire Releases Exclusive Audio Interview with ORHub, Inc. (ORHB)

ProBility Media Corp. (PBYA)

The QualityStocks Daily Newsletter would like to spotlight ProBility Media Corp. (PBYA). Today, ProBility Media Corp. closed trading at $0.5425, up 146.59%, on 100 volume with 1 trade. The stock’s average daily volume over the past 60 days is 1,447, and its 52-week low/high is $0.1205/$1.16.

ProBility Media Corp. (PBYA) based in Houston, TX, is an EdTech Company that is building the first full service training and career advancement brand for the skilled trades. Through both acquisitions and organic growth, ProBility is executing a disruptive strategy of defragmenting the market place of disparate companies servicing fifteen vertical categories in over sixty skilled trades. ProBility has positioned itself as a key industrial training resource for individuals, small- and medium-size businesses as well as enterprise customers offering consistent high-quality training services and materials for education, testing, and career advancement.

Through its Electrical Training Division, the company has become the biggest wholesaler of electrical codes and test preparation materials in the U.S., while its Construction Training Division is one of the largest certification providers in the country, with programs in 22 states, and continuing to grow. The company serves corporate accounts and government buyers, and also offers advisory services for companies of all sizes.

Companies currently under the ProBility Media conglomerate include:

  • Brown Technical Media Corp. – An online web business with multiple micro web sites featuring training materials and codes and standards sought by engineers, construction workers, scientists and other tradesmen in a wide variety of fields.
  • Brown Technical Publications – A proprietary publishing business generating copyrighted training materials for engineers, construction workers, scientists and other tradesman in a wide variety of fields.
  • 1ExamPrep – E-Learning, education and exam preparation for contractors via the cheapest, fastest and most effective exam prep school in the industry instituting our 4-point proven learning system.
  • National Electrical Wholesale Providers – In the business of distributing wholesale industrial, commercial and residential training materials including HVAC, plumbing and electrical.

ProBility's technology platform features virtual reality training for the crane business to be expanded into other industries, online subscription services for enterprise level companies, and recurring revenue streams. In addition, the company is already beginning to explore international expansion options, supported by the fact that other countries have adopted U.S. based codes, and have used U.S. training services.

The company's acquisition strategy targets operations that service engineering firms, electrical contractors, fabricators, plumbing contractors, pipe fitters, riggers, QC firms, and additional vocational industries. Disclaimer

ProBility Media Corp. Company Blog

ProBility Media Corp. News:

ProBility Media Corp. Files 10Q, Reports Third Consecutive Quarter of Revenue Growth

ProBility Media Corp. and GlobalSim Inc. Join Forces to Introduce Virtual Reality Training to the Crane Industry

ProBility Media Corp. Announces Philanthropic Initiative

National Waste Management Holdings, Inc. (NWMH)

The QualityStocks Daily Newsletter would like to spotlight National Waste Management Holdings, Inc. (NWMH). Today, National Waste Management Holdings, Inc. closed trading at $0.098, up 18.79%, on 1,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 24,941, and its 52-week low/high is $0.06/$0.51.

National Waste Management Holdings, Inc. (NWMH) is a solid waste management company offering comprehensive solutions for full waste diversion along Florida's west coast and in upstate New York. With an established base of long-term partnerships with municipal, institutional, commercial and industrial customers, along with a successful acquisition strategy, National Waste has set its course to become a leading waste diversion company.

National Waste's 54-acre landfill facility located in Hernando, Florida, handles annual average disposals of roughly 240,000 cubic yards of construction debris annually. The site also offers an array of ancillary services such as roll-off dumpster services, mulching services and recycling. While the landfill facility is already permitted for future expansion, National Waste's growth strategy also calls for the opening of new satellite offices in counties and states that neighbor its existing operations.

In addition to increasing its geographic foothold, National Waste employs a strategic acquisition model to increase its overall market share. In 2015, the company acquired Gateway Rolloff Services LP and Waste Recovery Enterprises LLC, which are expected to generate a combined $3.8 million in annual revenue for National Waste moving forward. In the second quarter of 2016, National Waste added Sivart Services to its roster, creating an immediate source of additional revenue and expanding its foothold in the northeast area of New York.

Management has confirmed its interest in additional acquisition targets while demonstrating its ability to effectively integrate and organically grow the company's existing acquisition companies and maintain efficient operations. Disclaimer

National Waste Management Holdings, Inc. Company Blog

National Waste Management Holdings, Inc. News:

National Waste Management Holdings, Inc. Expands Territory with Acquisition of Burts Refuse, LLC

National Waste Management Holdings, Inc. (NWMH) Expands Market Reach in New York with Acquisition of Northeast Data Destruction and Recycling

National Waste Management Holdings, Inc. Ends Year on High Note, Announces Final Acquisition of 2016

India Globalization Capital, Inc. (IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital, Inc. (NYSE: IGC). Today, India Globalization Capital, Inc. closed trading at $0.47, up 12.39%, on 931,931 volume with 1,400 trades. The stock’s average daily volume over the past 60 days is 220,759, and its 52-week low/high is $0.19/$0.651.

India Globalization Capital, Inc. (IGC) is a first mover in developing a portfolio of products using cannabis-based "combination therapies" for the treatment of pain and other conditions.

The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC's patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.

The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson's, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.

IGC's strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. "The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner," stated Ram Mukunda, CEO.

IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.

Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard's Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.

Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers' Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York's Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings. Disclaimer

India Globalization Capital, Inc. Company Blog

India Globalization Capital, Inc. News:

IGC Files Patent for Cannabis-based Combination Therapy for Treatment of Eating Disorders

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) CEO Featured in Benzinga Article

IGC Announces Third Quarter Financial Results

InMed Pharmaceuticals, Inc. (IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.358, up 9.49%, on 1,210,268 volume with 420 trades. The stock’s average daily volume over the past 60 days is 844,045, and its 52-week low/high is $0.05/$0.4261.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Pharmaceuticals' Unique Approach Featured in Forbes -- CFN Media

InMed's Exceptional Management Team Executes Ambitious Plan -- CFN Media

NetworkNewsWire Announces Publication of Discussion on the R&D of Cannabinoids for Medical Use

One Step Vending Corp. (KOSK)

The QualityStocks Daily Newsletter would like to spotlight One Step Vending Corp. (KOSK). Today, One Step Vending Corp. closed trading at $0.022, up 5.26%, on 2,380,292 volume with 215 trades. The stock’s average daily volume over the past 60 days is 1,117,485, and its 52-week low/high is $0.0026/$0.17.

One Step Vending Corp. (KOSK) is focused on growing through acquisitions and cooperative agreements with companies that have potential and capabilities of achieving sustainable growth and rapidly capturing market share. The company provides financing and operational business support while also helping build key growth strategies. Key business sectors actively targeted include food and refreshment services, self-checkout systems and mobile vending machines.

Corporate Refreshment Services Micro Markets Inc., a subsidiary of One Step Vending, is a self-checkout retailer that offers a wide range of food and beverages. With more than 150,000 units supplied to customers in the last twelve months, the company is experiencing triple-digit growth. Regardless if a traditional vending machine or the high-tech micro market is chosen, the location's patrons enjoy gourmet market deliciousness and quick market convenience.

Mainly targeting the office environment, the micro markets offer a fresh market-grab and go-food concept that doesn't cost the business anything to host. Each micro market can be customized for any size or look and feature an easy-to-use touch screen interface so anyone can easily shop, scan and pay for their items. Once installed, employees benefit from a diverse menu that includes healthy snacks, real food, classic vending favorites and much more.

The team behind this concept has been committed to staying at the forefront of vending technology for 15 years. By replacing traditional vending machines with micro markets, they experienced up to five times greater revenue in large accounts. Today, the groundwork is laid with unique capabilities and proven execution strategies.

With Corporate Refreshment Services setting the example, One Step Vending's mission is to support thousands of businesses in the realization of their business goals by delivering experiences that enrich and nourish. Fostering a winning network of associates and partners and building mutually loyalty and trust is core to the company's growth strategy. Disclaimer

One Step Vending Corp. Company Blog

One Step Vending Corp. News:

One Step Vending Corp. Installs Four New Micro Markets at a San Diego Pharmaceutical Facility

One Step Vending Corp. Installs Micro Market at Cushman Wakefield

One Step Vending Corp. Seeks Savvy Corporate Partners and Micro Market Investors for Mutually Beneficial Sales Growth Opportunities


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



(PBYA) +146.59%


Monster Alerts
(TSSI) +58.62%


(AKTX) +58.51%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251